What is Spruce Biosciences, Inc. 's market cap?

Spruce Biosciences, Inc. (SPRB) has a market capitalization of $142.4M and trades on NASDAQ.

Who are Spruce Biosciences, Inc. 's competitors?

Spruce Biosciences, Inc. 's key competitors include Neurocrine Biosciences, Inc., Fulcrum Therapeutics, Inc. Common Stock, Septerna, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Spruce Biosciences, Inc. partner with?

Spruce Biosciences, Inc. 's notable partners include Eli Lilly and Company, BioMarin Pharmaceutical Inc., HMNC Holding GmbH, and others.

Where is Spruce Biosciences, Inc. headquartered?

Spruce Biosciences, Inc. is headquartered in United States of America and employs approximately 22 people. It has been publicly traded since 2020.

Spruce Biosciences, Inc.

SPRB and SPRBD

Spruce Biosciences is a biopharmaceutical company dedicated to developing and commercializing novel therapies for neurological and endocrine disorders with significant unmet medical needs.

Market cap

$142.4M+2,557%

Table of contents

Earnings

Q1 2026 report

May 13, 2026

EPS-$8.94Miss by $1.62

Read the full report

Next report

Aug 13, 2026 (in a month)

EPS estimate-$6.04

Competitors

By market cap

Neurocrine Biosciences$18.2B+43.4%

Septerna, Inc.$1.7B+253%

XER

Xeris Biopharma Holdings, Inc.$1.5B+97.7%

Rezolute$494.0M+14.3%

LRM

Larimar Therapeutics$429.0M+109%

Fulcrum Therapeutics, Inc.$239.2M-36.9%

SPR

Spruce Biosciences, Inc. $142.4M—

Polaryx Therapeutics, Inc. $121.1M—

By revenue growth

Septerna, Inc.+7,296%

XER

Xeris Biopharma Holdings, Inc.+41.5%

Neurocrine Biosciences+28.6%

By net margin

Neurocrine Biosciences21.55%+8.9pp

XER

Xeris Biopharma Holdings, Inc.3.81%+24.1pp

Septerna, Inc.-49.88%+8,054pp

Profile

Spruce Biosciences is a biopharmaceutical company dedicated to developing and commercializing novel therapies for neurological and endocrine disorders with significant unmet medical needs. The company focuses on diseases with well-understood biology where current treatment options are either nonexistent or suboptimal. Its primary strategy involves advancing a pipeline of small molecule and biologic candidates through clinical development toward global commercialization.

Competitive position

A clinical-stage developer targeting ultra-rare conditions like MPS IIIB and CAH with orphan-designated candidates.

GeographiesUnited States, European Union, United Kingdom, Latin America, Asia

Customer segmentsRare disease patients, Specialized medical providers

Business modelBiopharmaceutical R&D, IP Licensing

SuppliersContract Manufacturing Organizations (CMOs), Academic research institutions, Raw material suppliers, Clinical trial sites

CustomersSpecialized medical centers, Third-party distributors, Biopharmaceutical strategic collaborators

CountryUnited States of America

Listed2020

Employees22.0

CEOJavier Szwarcberg

SectorHealthcare

IndustryBiotechnology

Websitesprucebiosciences.com

FilingsSEC EDGAR

Questions, answered.

What is Spruce Biosciences, Inc. 's market cap?: Spruce Biosciences, Inc. (SPRB) has a market capitalization of $142.4M and trades on NASDAQ.
Who are Spruce Biosciences, Inc. 's competitors?: Spruce Biosciences, Inc. 's key competitors include Neurocrine Biosciences, Inc., Fulcrum Therapeutics, Inc. Common Stock, Septerna, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Spruce Biosciences, Inc. partner with?: Spruce Biosciences, Inc. 's notable partners include Eli Lilly and Company, BioMarin Pharmaceutical Inc., HMNC Holding GmbH, and others.
Where is Spruce Biosciences, Inc. headquartered?: Spruce Biosciences, Inc. is headquartered in United States of America and employs approximately 22 people. It has been publicly traded since 2020.